Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Kato T, Mishima H, Ikenaga M, Murata K, Ishida H, Fukunaga M, Ota H, Tominaga S, Ohnishi T, Amano M, Ikeda K, Ikeda M, Sekimoto M, Sakamoto J, Monden M. Kato T, et al. Among authors: fukunaga m. Cancer Chemother Pharmacol. 2008 Feb;61(2):275-81. doi: 10.1007/s00280-007-0471-2. Epub 2007 Apr 11. Cancer Chemother Pharmacol. 2008. PMID: 17429630 Clinical Trial.
Multicenter phase II study of irinotecan plus bolus fluorouracil/l-leucovorin for metastasic colorectal cancer.
Mishima H, Ikenaga M, Ishida H, Iwamoto S, Morimoto T, Narahara H, Kato T, Tsujie M, Kitai T, Fukunaga M, Nakanishi M, Tsujinaka T, Furukawa H, Taguchi T; Osaka Gastrointestional Cancer Chemotherapy Study Group. Mishima H, et al. Among authors: fukunaga m. Anticancer Res. 2007 Mar-Apr;27(2):1003-8. Anticancer Res. 2007. PMID: 17465234 Free article. Clinical Trial.
A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
Hata T, Fukunaga M, Murata K, Uemura Y, Fukuzaki T, Ota H, Ohue M, Ohnishi T, Tanaka N, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Hata T, et al. Among authors: fukunaga m. Cancer Chemother Pharmacol. 2013 Jun;71(6):1657-63. doi: 10.1007/s00280-013-2143-8. Epub 2013 Mar 31. Cancer Chemother Pharmacol. 2013. PMID: 23543294 Clinical Trial.
Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.
Mizushima T, Fukunaga M, Sueda T, Ikeda M, Kato T, Kim HM, Kudo T, Murata K, Nishimura J, Hata T, Matsuda C, Yamamoto H, Doki Y, Mori M. Mizushima T, et al. Among authors: fukunaga m. Cancer Chemother Pharmacol. 2017 Jul;80(1):81-90. doi: 10.1007/s00280-017-3336-3. Epub 2017 May 16. Cancer Chemother Pharmacol. 2017. PMID: 28510802 Clinical Trial.
A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial.
Munemoto Y, Kanda M, Oba K, Kim HM, Takemoto H, Denda T, Nagata N, Takano N, Fukunaga M, Kataoka M, Tokunaga Y, Sakamoto J, Mishima H. Munemoto Y, et al. Among authors: fukunaga m. Cancer Chemother Pharmacol. 2018 May;81(5):829-838. doi: 10.1007/s00280-018-3556-1. Epub 2018 Mar 5. Cancer Chemother Pharmacol. 2018. PMID: 29508026 Clinical Trial.
Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
Kono T, Hata T, Morita S, Munemoto Y, Matsui T, Kojima H, Takemoto H, Fukunaga M, Nagata N, Shimada M, Sakamoto J, Mishima H. Kono T, et al. Among authors: fukunaga m. Cancer Chemother Pharmacol. 2013 Dec;72(6):1283-90. doi: 10.1007/s00280-013-2306-7. Cancer Chemother Pharmacol. 2013. PMID: 24121454 Free PMC article. Clinical Trial.
A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer.
Mizushima T, Ide Y, Murata K, Ohashi I, Yasumasa K, Fukunaga M, Takemoto H, Tamagawa H, Hasegawa J, Hata T, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Mizushima T, et al. Among authors: fukunaga m. Oncology. 2013;85(6):317-22. doi: 10.1159/000356018. Epub 2013 Nov 12. Oncology. 2013. PMID: 24247419 Clinical Trial.
Safety of fondaparinux to prevent venous thromboembolism in Japanese patients undergoing colorectal cancer surgery: a multicenter study.
Hata T, Yasui M, Murata K, Okuyama M, Ohue M, Ikeda M, Ueshima S, Kitani K, Hasegawa J, Tamagawa H, Fujii M, Ohkawa A, Kato T, Morita S, Fukuzaki T, Mizushima T, Sekimoto M, Nezu R, Doki Y, Mori M; Multi-Center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO). Hata T, et al. Surg Today. 2014 Nov;44(11):2116-23. doi: 10.1007/s00595-014-0911-7. Epub 2014 May 20. Surg Today. 2014. PMID: 24840400 Free PMC article.
1,294 results